Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Single Oral BIBT 1011 BS (Dabigatran Etexilate) in Healthy Subjects
NCT02182037Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2001
- Primary completion
- Sep 2001
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of dabigatran in thromboembolism (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Activated Partial Thromboplastin Time up to 48 hours and International Normalized Ratio up to 48 hours. Started Aug 2001; status: completed.
02
Drugs
dabigatran
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT02182037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02182037.